Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	42.27	45.79	35.44	11.36	55.74	32.59
Short-Term Investments	0.02	2.02	0.05	46.52	2.62	8.98
Cash & Short-Term Investments	42.29	47.81	35.49	57.88	58.36	41.56
Cash Growth	9.85%	34.69%	-38.67%	-0.83%	40.41%	35.31%
Accounts Receivable	0.26	0.64	0.75	0.3	50.84	0
Receivables	0.26	0.64	0.75	0.3	50.84	0
Prepaid Expenses	1.3	2.55	2.2	1.83	2.35	2.36
Restricted Cash	-	-	-	-	-	0.08
Total Current Assets	43.84	51	38.44	60	111.55	44
Property, Plant & Equipment	4.07	4.4	4.77	5.67	4.87	5.63
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Intangible Assets	31.7	46.54	46.56	46.69	46.82	47.03
Other Long-Term Assets	0.51	0.61	0.58	0.63	0.63	0.62
Total Assets	90.8	113.22	101.02	123.66	174.55	107.95
Accounts Payable	4.45	1.17	2.05	2.39	3.54	2.61
Accrued Expenses	-	4.26	4.22	6.22	24.25	3.67
Short-Term Debt	-	-	-	-	-	0.52
Current Portion of Leases	1.05	1.15	0.88	0.95	0.83	0.76
Current Unearned Revenue	5.26	7.39	10.81	9.42	18.12	0.19
Other Current Liabilities	-	-	-	-	0.38	0.01
Total Current Liabilities	10.76	13.98	17.96	18.98	47.12	7.77
Long-Term Leases	1.11	1.36	2.07	2.94	1.97	2.54
Long-Term Unearned Revenue	12.75	14.43	18.69	27.73	32.45	-
Long-Term Deferred Tax Liabilities	0.27	0.27	0.27	2.08	2.08	2.08
Other Long-Term Liabilities	18.8	6.16	-	0	0.03	0.44
Total Liabilities	43.69	36.21	39	51.73	83.65	12.82
Common Stock	490.55	484.72	451.34	440.28	434.53	393.94
Retained Earnings	-438.07	-403.47	-384.86	-363.37	-337.1	-294.08
Comprehensive Income & Other	-4.1	-2.88	-3.07	-3.57	-5.21	-3.67
Total Common Equity	48.39	78.38	63.42	73.34	92.22	96.2
Minority Interest	-1.27	-1.37	-1.4	-1.4	-1.32	-1.07
Shareholders' Equity	47.11	77.01	62.02	71.94	90.9	95.13
Total Liabilities & Equity	90.8	113.22	101.02	123.66	174.55	107.95
Total Debt	2.15	2.51	2.95	3.9	2.8	3.83
Net Cash (Debt)	40.13	45.29	32.54	53.98	55.56	37.74
Net Cash Growth	12.91%	39.19%	-39.72%	-2.84%	47.22%	47.71%
Net Cash Per Share	0.18	0.23	0.19	0.32	0.34	0.25
Filing Date Shares Outstanding	228.36	228.36	188.53	170.15	169.71	161.64
Total Common Shares Outstanding	228.36	220.42	174.99	170.09	169.48	153.1
Working Capital	33.09	37.02	20.48	41.02	64.43	36.23
Book Value Per Share	0.21	0.36	0.36	0.43	0.54	0.63
Tangible Book Value	6.01	21.17	6.19	15.98	34.73	38.5
Tangible Book Value Per Share	0.03	0.10	0.04	0.09	0.20	0.25
Machinery	-	4.13	3.61	3.26	3.47	3.63
Leasehold Improvements	-	2.3	2.31	2.15	2.54	2.47

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q